A multicenter, double-blind, placebo-controlled trial in China evaluating APL-1202 in combination with intravesical chemotherapy for the treatment of patients with intermediate- or high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) relapsed from chemotherapies.

Trial Profile

A multicenter, double-blind, placebo-controlled trial in China evaluating APL-1202 in combination with intravesical chemotherapy for the treatment of patients with intermediate- or high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) relapsed from chemotherapies.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs APL 1202 (Primary) ; Epirubicin
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCRUE-1
  • Sponsors Asieris Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2017 New trial record
    • 30 Mar 2017 According to an Asieris Pharmaceuticals media release, design of this trial has been accepted by the Center for Drug evaluation (CDE) of CFDA.
    • 30 Mar 2017 According to an Asieris Pharmaceuticals media release, first patient has been treated at Shanghai Fudan University Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top